- Home
- PAXS vs KROS Comparison
PAXS vs KROS Comparison
Compare PAXS & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAXS | KROS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 721.4M | 584.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PAXS | KROS |
|---|---|---|
| Price | $14.47 | $10.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $22.25 |
| AVG Volume (30 Days) | 185.2K | ★ 376.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.63 | $9.12 |
| 52 Week High | $16.56 | $22.55 |
Technical Indicators
Market Signals| Indicator | PAXS | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 28.06 | 17.12 |
| Support Level | N/A | N/A |
| Resistance Level | $16.07 | $15.21 |
| Average True Range (ATR) | 0.30 | 0.71 |
| MACD | -0.09 | -0.22 |
| Stochastic Oscillator | 7.41 | 7.37 |
Price Performance
Historical ComparisonAbout PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.